









Markets
/
Stocks
/
nasdaq-sonn
/

Sonnet Biotherapeutics Holdings Inc

SONN

View Detailed Chart

2.810USD

-0.510-15.36%

Market hours （ET）Quotes delayed by 15 min

8.78MMarket Cap

LossP/E TTM



Sonnet Biotherapeutics Holdings Inc

2.810

-0.510-15.36%

Overview Company Financials

Financials

Intraday

30m

Today

-15.36%

5 Days

-29.57%

1 Month

-28.32%

6 Months

+76.73%

Year to Date

+92.47%

1 Year

-55.08%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 1 analysts

BUY

Current Rating

20.000

Target Price

611.74%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Sonnet Biotherapeutics Holdings Inc

SONN

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(5)

Neutral(3)

Buy(2)

Indicators

Sell(1)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.036

Neutral

RSI(14)

40.458

Neutral

STOCH(KDJ)(9,3,3)

4.399

Oversold

ATR(14)

1.079

Low Volatility

CCI(14)

-90.960

Neutral

Williams %R

98.696

Oversold

TRIX(12,20)

0.981

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

3.332

Sell

MA10

3.974

Sell

MA20

5.301

Sell

MA50

2.937

Sell

MA100

2.131

Buy

MA200

2.310

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).

Ticker SymbolSONN

CompanySonnet Biotherapeutics Holdings Inc

CEOMr. Raghu Rao

Websitehttps://www.sonnetbio.com/